L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-
| Title | Journal |
|---|---|
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | Chemical research in toxicology 20150518 |
| Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma. | Expert opinion on pharmacotherapy 20130301 |
| Lack of expression of MTAP in uncommon T-cell lymphomas. | Clinical lymphoma, myeloma & leukemia 20121001 |
| Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. | Clinical lymphoma, myeloma & leukemia 20120801 |
| Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20120801 |
| Cutaneous T-cell lymphoma's confounding nature. | Journal of the National Cancer Institute 20120606 |
| Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20120601 |
| Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120601 |
| Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. | Blood 20120503 |
| Clinical development of new formulations of cytotoxics in solid tumors. | Current opinion in oncology 20120501 |
| Hepatosplenic gamma-delta T-cell lymphoma in a female patient after delivery. | Hematology reports 20120102 |
| Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. | Cancer management and research 20120101 |
| Pralatrexate (Folotyn). | Skinmed 20120101 |
| Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma. | Clinical Medicine Insights. Oncology 20120101 |
| Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas. | European journal of haematology 20111201 |
| Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111101 |
| Peripheral T-cell lymphomas: diagnosis and treatment options. Proceedings from a live roundtable, August 17, 2011, Kauai, Hawaii. | Clinical advances in hematology & oncology : H&O 20111101 |
| Targeted molecular therapy in peripheral T-cell lymphomas. | Expert review of hematology 20111001 |
| Peripheral T-cell lymphoma--not otherwise specified. | Critical reviews in oncology/hematology 20110901 |
| Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma. | Expert opinion on drug metabolism & toxicology 20110901 |
| Dihydrofolate reductase protects endothelial nitric oxide synthase from uncoupling in tetrahydrobiopterin deficiency. | Free radical biology & medicine 20110601 |
| Hematology: relapsed and refractory PTCL--into the therapeutic abyss. | Nature reviews. Clinical oncology 20110601 |
| Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110320 |
| New drug therapies in peripheral T-cell lymphoma. | Expert review of anticancer therapy 20110301 |
| Therapeutic advances in cutaneous T-cell lymphoma. | Skin therapy letter 20110201 |
| Single agent and combination studies of pralatrexate and molecular correlates of sensitivity. | British journal of cancer 20110118 |
| Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma. | Therapeutics and clinical risk management 20110101 |
| A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma. | ISRN hematology 20110101 |
| An update on the management of peripheral T-cell lymphoma and emerging treatment options. | Journal of blood medicine 20110101 |
| Investigational approaches for mesothelioma. | Frontiers in oncology 20110101 |
| Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. | Investigational new drugs 20101201 |
| The antifolates: evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs. | Current opinion in investigational drugs (London, England : 2000) 20101201 |
| A case of blastic plasmacytoid dendritic cell neoplasm initially mimicking cutaneous lupus erythematosus. | Cancer research and treatment : official journal of Korean Cancer Association 20101201 |
| Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. | Clinical cancer research : an official journal of the American Association for Cancer Research 20101015 |
| Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20100715 |
| Pralatrexate (Folotyn) for peripheral T-cell lymphoma. | The Medical letter on drugs and therapeutics 20100712 |
| Pralatrexate: basic understanding and clinical development. | Expert opinion on pharmacotherapy 20100701 |
| Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. | Oncology (Williston Park, N.Y.) 20100601 |
| New targets of therapy in T-cell lymphomas. | Current drug targets 20100401 |
| Novel agents in development for peripheral T-cell lymphoma. | Seminars in hematology 20100401 |
| Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan. | Seminars in hematology 20100401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100401 |
| Anticancer agents against malaria: time to revisit? | Trends in parasitology 20100301 |
| StatBite: FDA oncology drug product approvals in 2009. | Journal of the National Cancer Institute 20100224 |
| Current and emerging treatment strategies for cutaneous T-cell lymphoma. | Drugs 20100212 |
| Pralatrexate - from bench to bedside. | Drugs of today (Barcelona, Spain : 1998) 20100201 |
| Response to hydralazine-valproate in a patient with mycosis fungoides. | Case reports in medicine 20100101 |
| An update in management of noncutaneous T-cell lymphomas. | Advances in hematology 20100101 |
| Peripheral T-cell lymphoma: review and updates of current management strategies. | Advances in hematology 20100101 |
| Cancer chemotherapy: targeting folic acid synthesis. | Cancer management and research 20100101 |
| FDA approves pralatrexate for treatment of rare lymphoma. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20091101 |
| Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. | Cancer chemotherapy and pharmacology 20091001 |
| Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090910 |
| A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. | Clinical pharmacology and therapeutics 20090801 |
| Novel therapies for peripheral T-cell non-Hodgkin's lymphomas. | Current opinion in hematology 20090701 |
| Importance of early splenectomy in patients with hepatosplenic T-cell lymphoma and severe thrombocytopenia. | Annals of surgical oncology 20090701 |
| Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions. | Blood 20090618 |
| T-cell lymphomas. | Clinical advances in hematology & oncology : H&O 20090601 |
| Pralatrexate, a new hope for aggressive T-cell lymphomas? | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20090401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20090301 |
| Optimizing chemotherapeutic strategies for peripheral T-cell lymphomas. | Clinical lymphoma & myeloma 20081201 |
| Novel therapies for cutaneous T-cell lymphomas. | Clinical lymphoma & myeloma 20081201 |
| Novel therapies in peripheral T-cell lymphomas. | Current oncology reports 20080901 |
| Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. | IDrugs : the investigational drugs journal 20080701 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20080501 |
| CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. | Journal of the American Academy of Dermatology 20080301 |
| Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. | British journal of haematology 20071101 |
| Management of advanced-stage peripheral T-cell lymphomas. | Current hematologic malignancy reports 20071001 |
| A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070501 |
| Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20070401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20070401 |
| Pralatrexate: an emerging new agent with activity in T-cell lymphomas. | Current opinion in oncology 20061101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20061101 |
| New drugs for the treatment of advanced-stage diffuse large cell lymphomas. | Seminars in hematology 20061001 |
| A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors. | Cancer chemotherapy and pharmacology 20060501 |
| The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060201 |
| 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030601 |
| Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. | Leukemia & lymphoma 20030601 |
| Experimental therapeutics with a new 10-deazaaminopterin in human mesothelioma: further improving efficacy through structural design, pharmacologic modulation at the level of MRP ATPases, and combined therapy with platinums. | Clinical cancer research : an official journal of the American Association for Cancer Research 20011001 |